Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of interferon relapsers.

I Jacobson1

  • 1Division of GI and Hepatology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York 10021, USA.

The American Journal of Medicine
|February 1, 2000
PubMed
Summary

Relapse after interferon therapy for hepatitis C virus (HCV) is common. Combination therapy with interferon and ribavirin offers a highly effective second-line treatment for relapsed patients, especially those with specific viral characteristics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.

Alimentary pharmacology & therapeutics·2013
Same author

B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.

Clinical and experimental immunology·2012
Same author

Injuries among Swedish female elite football players: a prospective population study.

Scandinavian journal of medicine & science in sports·2007
Same author

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

Journal of pharmacological and toxicological methods·2006
Same author

Analysis of the formed track in solid state materials using atomic force microscopy.

Radiation protection dosimetry·2002
Same author

Chronic oesophagitis in the cat.

Scandinavian journal of gastroenterology·2001

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Relapse following interferon monotherapy for chronic hepatitis C virus (HCV) infection is a significant clinical challenge.
  • High rates of relapse occur after both 6- and 12-month interferon courses, with limited success in re-treatment with interferon alone.

Purpose of the Study:

  • To evaluate the efficacy of combination therapy with interferon and ribavirin as a second-line treatment for patients who relapsed after initial interferon therapy for chronic HCV.
  • To identify predictors of sustained virologic response to combination therapy in relapsed HCV patients.

Main Methods:

  • A multicenter international trial was conducted to compare interferon plus ribavirin combination therapy with interferon monotherapy in relapsed HCV patients.
  • Patient characteristics, viral factors (genotype, viral load), and treatment outcomes (sustained virologic response, biochemical and virologic response, histologic improvement) were analyzed.

Main Results:

  • Combination therapy with interferon and ribavirin achieved a sustained virologic response rate of nearly 50%, a tenfold increase compared to interferon monotherapy (5%).
  • In patients with non-1 genotype and HCV RNA levels ≤2 million copies/mL, the sustained response rate to combination therapy was 100%.
  • Histologic improvement was frequently observed alongside biochemical and virologic responses.

Conclusions:

  • Interferon and ribavirin combination therapy is the preferred second-line treatment for patients relapsing after initial interferon therapy for chronic HCV.
  • HCV genotype (non-1) and baseline viral load (≤2 million copies/mL) are strong predictors of successful treatment response to combination therapy.

Related Experiment Videos